Unity Biotechnology issues Series A Preferred with 600M votes to facilitate dissolution approval

Unity Biotechnology, Inc.

Issued one Series A Preferred share to sole director Craig R. Jalbert for $1.00; share carries 600M votes, only on dissolution proposal.
Series A votes in same proportion as common votes cast, excluding abstentions and broker non-votes, neutralizing their effect.
Prior to issuance, dissolution required majority of outstanding common; now requires majority of voting power (common + Series A) with proportional voting.
Series A automatically transfers back to company for no consideration upon stockholder approval of dissolution.
Company delisted from Nasdaq on July 9, 2025; now trades OTC Pink under UNBX.

item 1.01item 5.03item 3.02item 3.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.